{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "be2ffb2a",
   "metadata": {},
   "source": [
    "IMMUNE SYSTEM ODES\n",
    "\n",
    "patient constant H_i.\n",
    "\n",
    "Parameters:\n",
    "  Effector: a_E, b_EA, a_EHi, d_EP, d_EC (might need to add heavy side fucntion for chemo) (i think i can get away with just a_EHi, might not need a_E) \n",
    "  Helper:   a_H, b_HA, d_HP, d_HC, sigma_H, [b_HE=0]\n",
    "  TIL:      a_I, b_IA, d_IP, d_IC\n",
    "  Exhaustion: p_0, p_A, p_C, p_H, delta_P, rho_blk\n",
    "\n",
    "RHS:\n",
    "  dE = a_E*E + b_EA*E*A + a_EHi*E*H_i - d_EP*E*P - d_EC*E*C \n",
    "  dH = a_H*H + b_HA*H*A - d_HP*H*P - d_HC*H*C + b_HE*H*E\n",
    "  dI = a_I*I + b_IA*I*A - d_IP*I*P - d_IC*I*C + u_I(t)\n",
    "  dP = p_H*H_i + p_A*A + p_C*C - delta_P*P \n",
    "\n",
    "  Breakdown: Effector cell ode\n",
    "  a_E*E - net growth rate (proliferation-death) of baseline CD8+ cells\n",
    "  b_EA - added stimualtion of CD8+ cells due to tumor presence\n",
    "  a_EHi - Flow of CD8+ cells depended upon patient immune system (unique to patient)\n",
    "  d_EP - blockage of cd8+ cells due to PD-L1 cells\n",
    "  d_EC - death of CD8+ cells due to chemo therapy\n",
    "\n",
    "  Breakdown: CD4+ (Helper Cells)\n",
    "  a_H - baseline flow of cd4+ cells (proliferation-death rate)\n",
    "  b_HA - added flow of helper cells due to tumor cell presence\n",
    "  d_HP - blockage of CD4+ cells due to PD-L1\n",
    "  d_HC - chemo induced death of CD4+ cells\n",
    "  b_HE - (optional) Helper–effector synergy: bidirectional stimulation between CD4⁺ and CD8⁺ subsets\n",
    "\n",
    "  Breakdown: Immune Cell Influx\n",
    "  a_I - Intrinsic net change of infused TIL population\n",
    "  b_IA - Tumor-driven proliferation: TILs expand in response to available antigen targets\n",
    "  d_IP - Functional suppression: exhaustion or PD-L1–mediated inhibition of infused T cells\n",
    "  d_IC - damage or depletion of infused TILs due to chemotherapy exposure.\n",
    "  u_I(t) - external TIL infusion rate or engraftment event (defines treatment timing and dosage)\n",
    "\n",
    "  Breakdown: Exhaustion/Checkpoint \n",
    "  p_H*H_i - patient based baseline flow of PD-L1\n",
    "  p_A - Tumor-induced upregulation of PD-L1 proportional to tumor burden or antigen presence\n",
    "  p_C - increase in PD-L1 expression following chemotherapy-related stress\n",
    "  delta_P - Natural decay or receptor turnover of PD-L1 expression over time.\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "0eb98f45",
   "metadata": {
    "vscode": {
     "languageId": "plaintext"
    }
   },
   "outputs": [],
   "source": [
    "CHEMO THERAPY ODES\n",
    "\n",
    "Parameters:\n",
    "u_x(t) = concentration of dosage of treatment at time t\n",
    "lambda_x*X = rate of clearance from the body\n",
    "\n",
    "Adriamycin\n",
    "dA/dt = u_a(t) - lamda_a*A \n",
    "Cytoxan\n",
    "dC/dt = u_c(t) - lamda_c*C\n",
    "Taxol\n",
    "dT/dt = u_T(t) - lamda_t*t\n",
    "Tamoxifen\n",
    "dTam = u_Tam(t) - lamda_tam*Tam\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "9c2072a6",
   "metadata": {
    "vscode": {
     "languageId": "plaintext"
    }
   },
   "outputs": [],
   "source": [
    "BREAST CANCER TUMOR ODE\n",
    "\n",
    "- T(t): tumor burden (cells, mm^3, or normalized units)\n",
    "- ER(t): ER+ activity (0–1 or normalized score)\n",
    "- PR(t): PR+ activity (0–1 or normalized score)\n",
    "- Ki67(t): proliferation index (0–1 or fraction)\n",
    "- ESR1m(t): ESR1 mutation activity/burden (0–1)\n",
    "- PI3K(t): PI3K/AKT/mTOR pathway activation (0–1)\n",
    "- ctDNA(t): circulating tumor DNA burden (e.g., ng/mL or normalized)\n",
    "\n",
    "inputs for carrying capacity\n",
    "- BMI(t) or BSA(t)  — either one (normalize to 0–1)\n",
    "- VEGF(t)           — angiogenesis proxy (use a saturating transform)\n",
    "- Nutrient(t)       — a combined oxygen+glucose supply index (normalize or saturate)\n",
    "\n",
    "We build a time-varying carrying capacity K(t) from these signals.\n",
    "\n",
    "Time-varying carrying capacity\n",
    "- Normalize each signal to ~[0,1] (z-score or min-max).\n",
    "- Define:\n",
    "  K(t) = K0 * [ 1 + w_BMI * BMI_hat(t) + w_VEGF * sat_VEGF(VEGF(t)) + w_N * sat_N(Nutrient(t)) ]\n",
    "\n",
    "Notes:\n",
    "- sat_VEGF(z) or sat_N(z) can be z / (K + z) to avoid runaway.\n",
    "\n",
    "## Modeling style\n",
    "We use a generalized Lotka–Volterra structure: each variable’s rate = (itself) * (intrinsic rate + interactions) + optional source/sink.\n",
    "Keep parameters nonnegative where biologically sensible, and clamp fraction-like states (ER, PR, Ki67, ESR1m, PI3K) to [0,1] in code.\n",
    "\n",
    "---\n",
    "\n",
    "## ODEs \n",
    "\n",
    "### Tumor burden\n",
    "dotT = T * [\n",
    "    r_T\n",
    "  + a_T_Ki67 * Ki67\n",
    "  + a_T_ER   * ER\n",
    "  + a_T_PR   * PR\n",
    "  + a_T_ESR1m* ESR1m\n",
    "  + a_T_PI3K * PI3K\n",
    "  - (beta_T * T / K(t))  # logistic crowding with time-varying K(t)\n",
    "]\n",
    "\n",
    "### ER activity\n",
    "dotER = ER * ( r_ER + a_ER_T * T - d_ER ) + c_ER_from_PR * PR * (1 - ER)\n",
    "\n",
    "### PR activity\n",
    "dotPR = PR * ( r_PR + a_PR_T * T - d_PR ) + c_PR_from_ER * ER * (1 - PR)\n",
    "\n",
    "### Ki-67 proliferation index\n",
    "dotKi67 = Ki67 * ( r_Ki + a_Ki_T * T + a_Ki_PI3K * PI3K - d_Ki )\n",
    "\n",
    "### ESR1 mutation activity/burden\n",
    "dotESR1m = ESR1m * ( r_Em + a_Em_T * T - d_Em ) + s_Em_from_ctDNA * ctDNA * (1 - ESR1m)\n",
    "\n",
    "### PI3K pathway activation\n",
    "dotPI3K = PI3K * ( r_P + a_P_T * T - d_P ) + a_P_from_ER * ER * (1 - PI3K)\n",
    "\n",
    "### ctDNA burden\n",
    "dotctDNA = q_T * T + q_Em * ESR1m * T - delta_ct * ctDNA\n",
    "\n",
    "---\n",
    "\n",
    "## What each term means \n",
    "- r_*: intrinsic net change when isolated (per-time).\n",
    "- a_*_*: interaction coefficients (positive increases, negative decreases).\n",
    "- d_*: decay/turnover toward baseline.\n",
    "- c_*_from_*: cross-talk between biomarkers; (1 - x) keeps fraction-like variables in [0,1].\n",
    "- q_T, q_Em: ctDNA production from total tumor and ESR1m-driven resistant clones.\n",
    "- delta_ct: ctDNA clearance.\n",
    "- beta_T: strength of logistic self-limitation via K(t).\n",
    "- K(t): capacity supply from BMI/BSA, VEGF, Nutrient; prevents unrealistic growth.\n",
    "\n",
    "## Practical notes\n",
    "- Bounding: clamp ER, PR, Ki67, ESR1m, PI3K to [0,1] each integration step or keep the (1 - x) terms.\n",
    "- Therapy hooks (optional for later): endocrine therapy can reduce a_T_ER and a_T_PR; PI3K inhibitors reduce a_T_PI3K or increase d_P; chemo can be added as extra death terms on T and as modifiers on biomarkers.\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "e2113310",
   "metadata": {},
   "source": [
    "TOXCICITY ODE\n",
    "- Let D_k(t) be drug exposures (e.g., plasma conc. from PK), one per agent k.\n",
    "- For each D_k, a one-compartment PK is enough to start:\n",
    "  dD_k/dt = -k_elim_k * D_k + u_k(t)\n",
    "  where u_k(t) is the dosing input (bolus or infusion), k_elim_k = ln(2) / t_half_k.\n",
    "\n",
    "- Use saturating \"toxicity drive\" from each drug:\n",
    "  tox_k(D_k) = Emax_k * D_k / (EC50_k + D_k)\n",
    "  (You can add Hill>1 later if needed.)\n",
    "\n",
    "- Recovery terms pull biomarkers back toward baseline; damage terms push them away.\n",
    "\n",
    "------------------------------------------------------------\n",
    "OPTION A — Single scalar toxicity score (fast/compact)\n",
    "------------------------------------------------------------\n",
    "State:\n",
    "- Xtox(t) in [0, 1] as an overall toxicity burden (0 none, 1 severe).\n",
    "\n",
    "Dynamics:\n",
    "- dotXtox = ( sum_k w_k * tox_k(D_k) ) \n",
    "            + w_int * Interactions(t)\n",
    "            - r_rec * Xtox\n",
    "\n",
    "Notes:\n",
    "- w_k >= 0 scale each drug's contribution.\n",
    "- Interactions(t) is optional (e.g., chemo + PD-1 co-toxicity); else set to 0.\n",
    "- r_rec > 0 is global recovery.\n",
    "- Clamp Xtox to [0,1] in code.\n",
    "\n",
    "Pros/cons:\n",
    "- + Simple, stable, easy to fit when data is sparse.\n",
    "- – Low clinical interpretability; hard to map to specific adverse events.\n",
    "\n",
    "----------------------------------------------------------------\n",
    "OPTION B — 4-biomarker toxicity model (interpretable/reusable)\n",
    "----------------------------------------------------------------\n",
    "States (with suggested ranges):\n",
    "- x_cardiac(t)  in [0,1]  (cardiac damage score; 0 none, 1 severe)\n",
    "- x_neut(t)     in [0,1]  (normalized neutrophil count; 1 healthy, 0 profoundly low)\n",
    "- x_immune(t)   in [0,1]  (immune competence; 1 healthy, 0 severely compromised)\n",
    "- x_neuro(t)    in [0,1]  (neuropathy severity; 0 none, 1 severe)\n",
    "\n",
    "Drug-specific drives:\n",
    "- For each drug k, define coefficients on each biomarker: \n",
    "  w_k_card, w_k_neut, w_k_imm, w_k_neuro >= 0.\n",
    "- tox_k(D_k) as above.\n",
    "\n",
    "Couplings you may want:\n",
    "- Immune ↔ neutrophils: neutropenia tends to reduce immune competence.\n",
    "- Neuropathy accumulates slowly and recovers slowly.\n",
    "- Cardiac injury is often cumulative with slow repair.\n",
    "\n",
    "Equations (ASCII, per-time units):\n",
    "\n",
    "1) Cardiac damage score (higher is worse)\n",
    "dotx_cardiac = ( sum_k w_k_card * tox_k(D_k) ) \n",
    "               + w_card_accum * x_cardiac * (1 - x_cardiac)   # cumulative stress\n",
    "               - r_card_rec * x_cardiac\n",
    "\n",
    "2) Neutrophil fraction (higher is better)\n",
    "dotx_neut = - ( sum_k w_k_neut * tox_k(D_k) ) * x_neut        # loss scales with current pool\n",
    "            + r_neut_rec * (1 - x_neut)                       # marrow recovery towards 1\n",
    "\n",
    "3) Immune competence (higher is better)\n",
    "dotx_immune = - ( sum_k w_k_imm * tox_k(D_k) ) * x_immune\n",
    "              + r_imm_rec * (1 - x_immune)\n",
    "              + c_neut_to_imm * (x_neut - x_immune)           # neutrophils support immune tone\n",
    "\n",
    "4) Neuropathy severity (higher is worse)\n",
    "dotx_neuro = ( sum_k w_k_neuro * tox_k(D_k) )\n",
    "             + w_neuro_accum * x_neuro * (1 - x_neuro)        # slow accumulation\n",
    "             - r_neuro_rec * x_neuro\n",
    "\n",
    "Bounding/implementation:\n",
    "- After each step, clamp states to valid ranges:\n",
    "  x_cardiac = min(max(x_cardiac, 0), 1), etc.\n",
    "- Start with small w_accum terms; set to 0 initially if unstable.\n",
    "\n",
    "------------------------------------------------------------\n",
    "Optional aggregate readouts\n",
    "------------------------------------------------------------\n",
    "- Overall toxicity index for dashboards:\n",
    "  Xtox = v_card*x_cardiac + v_neut*(1 - x_neut) \n",
    "         + v_imm*(1 - x_immune) + v_neuro*x_neuro\n",
    "  (Choose v_* to reflect clinical priorities.)\n",
    "- Grade triggers (pseudo-CTCAE):\n",
    "  if x_neut < 0.5 -> \"Grade ≥3 neutropenia risk\"\n",
    "  if x_cardiac > 0.3 rising -> \"Cardiac monitoring\"\n",
    "  if x_neuro > 0.4 -> \"Neuropathy dose-hold candidate\"\n",
    "\n",
    "------------------------------------------------------------\n",
    "Calibration tips\n",
    "------------------------------------------------------------\n",
    "- Map x_neut to ANC: x_neut ≈ clamp( ANC / ANC_baseline , 0, 1 ).\n",
    "- Map x_cardiac to troponin/EF: choose a monotone transform to [0,1].\n",
    "- x_immune can be composite (lymphocytes, CD4/CD8 ratio, clinical judgement).\n",
    "- x_neuro can be symptom score or exam-based scale normalized to [0,1].\n",
    "- Start with one drug and one biomarker to verify signs/magnitudes; then expand.\n",
    "\n",
    "------------------------------------------------------------\n",
    "Minimal parameter set (per biomarker)\n",
    "------------------------------------------------------------\n",
    "- Recovery: r_card_rec, r_neut_rec, r_imm_rec, r_neuro_rec\n",
    "- Accumulation (optional): w_card_accum, w_neuro_accum\n",
    "- Drug weights per biomarker: w_k_card, w_k_neut, w_k_imm, w_k_neuro\n",
    "- PK: t_half_k (or k_elim_k), EC50_k, Emax_k for each drug k\n",
    "- Cross-talk: c_neut_to_imm\n",
    "\n",
    "------------------------------------------------------------\n",
    "When to choose A vs B\n",
    "------------------------------------------------------------\n",
    "- Choose A (single Xtox) if you have only sparse outcomes (e.g., “dose reduced yes/no”).\n",
    "- Choose B (4D biomarkers) if you have access to labs/signs (ANC, troponin/EF, symptom scores).\n",
    "- You can always compute Xtox as an aggregate of the 4D model later.\n"
   ]
  }
 ],
 "metadata": {
  "language_info": {
   "name": "python"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
